Back to dashboard
All PlansAdministrativeMedium impact

08.00.74ac, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors

Independence Blue Cross·Pharmacy
Effective date
Not stated
We identified it
Jul 2, 2026
Days to comply
—

Summary

Failed to analyze policy change

Action Required

Action needed
Manual review required

Related policy hubs

08.00.74ac, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors | Independence Blue Cross | PolicyChanges.app